Orange County Business Journal

Peregrine Pharmaceuticals Back Up

Vita Reed Tuesday, September 25, 2012

Tustin-based Peregrine Pharmaceuticals Inc.’s shares continued their roller-coaster ride today after yesterday’s steep drop-off.

Shares of the drug developer rose 44% in midday trading to a market value of about $171 million.

Peregrine shares fell by more than 70% yesterday after company officials told analysts that they shouldn’t rely on clinical data about bavituximab, which it is developing as a lung cancer treatment.

The drug maker said Monday that it discovered what it called “major discrepancies” between some patient sample test results and other data in a mid-stage trial data.

Peregrine’s collapse followed a big share jump in early September after it said patients who were treated with bavituximab in the trial lived twice as long as those who only received chemotherapy.

Facebook Twitter Linked-In